Wiggin and Dana recently represented Notable Labs, Inc. (Notable), a clinical stage therapeutics platform company developing predictive precision medicines for cancer patients, in its merger with VBL Therapeutics (Nasdaq: VBLT) and associated financing transaction. Through the merger, the combined company’s efforts will now be on the advancement of Notable’s proprietary Predictive Precision Medicines Platform (“PPMP”) and therapeutic pipeline focused on cancer patients with high unmet medical needs.
On October 17, shares of the combined company, renamed Notable Labs, Ltd., will begin trading on NASDAQ, under the new ticker symbol “NTBL”. Under the terms of the merger agreement, Notable stockholders now own about 75% and VBL shareholders own roughly 25% of the combined company.
$10.3 million in new funding was also invested prior to closing of the merger by Builders VC, B Capital Group, Y Combinator, First Round Capital, and Founders Fund.
The Wiggin deal team consisted of Evan Kipperman, Michael Grundei, James Greifzu, Elishama Rudolph, Patti Melick, and Aaron Ryne.
To learn more and read the official press release, please click here.